Original Article

A Study on the Association of Interleukin-1 Cluster with Genetic Risk in Bipolar I Disorder in Iranian Patients: A Case-control Study


The pathogenesis of Bipolar I Disorder (BP-I) involves immune-mediated mechanisms, especially an imbalance in pro-inflammatory/anti-inflammatory cytokines in plasma or cerebrospinal fluid. Interleukin-1 (IL-1) gene cluster, coding some of these pro-inflammatory cytokines, might play a role in various neuropathologies related to neuron inflammation. The aim of the present study was to investigate the possible role of IL-1 gene cluster polymorphisms in determining the susceptibility to BP-I in Iranian population. 48 patients with BP-I in Mashhad (in north-eastern Iran), diagnosed by two psychiatrists using SCID (structured clinical interview for DSM disorders) were selected through convenient sampling and were compared with 47 healthy controls, voluntarily enrolled in the study. Patients with non-Persian ethnicity, history of immunoallergic disorders, endocrinopathies, neurologic disorders, and substance-induced mood disorders were excluded from both case and control groups. Genotyping of IL-1 gene cluster polymorphisms, including IL-1a-889, IL-1b +3954, IL-1b-511, and IL-1RN (VNTR) were carried out using Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and compared by SPSS using Fisher’s exact and chi-square tests. The frequency of IL-1b-511 CC genotype and C/T allelic frequency were significantly different between BMD patients and healthy controls (p=0.04 and p=0.02, respectively). Among patients, -511 T allele was significantly more frequent in those with a positive history of major depression. Moreover, +3954 T allele was significantly more frequent in early onset BMD patients. The results suggest a positive association between IL-1 gene cluster variation and BP-I. This polymorphism may contribute to genetic vulnerability through its possible role in neuron inflammation.

  1. Rafiei A, Hosseini SH, Taheri M, Hosseni-khah Z, Hajilooi M, Mazaheri Z. Influence of IL-1RN Intron 2 Variable Number of Tandem Repeats (VNTR) Polymorphism on Bipolar Disorder. Neuropsychobiology 2013; 67(2):116–21.
  2. Altinbas K, Guloksuz S, Ora T. Metabolic syndrome prevalence in different affective temperament profiles in bipolar-I disorder. Rev Bras Psiquiatr 2013; 35(2):131–5.
  3. Burmeister M, McInnis MG, Zollner S. Psychiatric genetics: progress amid controversy. Nat Rev Genet 2008; 9(7):527–40.
  4. Mcguffin P, Rijsdijk F, Andrew M, Sham P, Katz R, Cardno A. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch Gen Psychiatry 2003; 60(5):497–502.
  5. Papiol S, Molina V, Desco M, Rosa A, Reig S, Sanz J, et al. Gray matter deficits in bipolar disorder are associated with genetic variability at interleukin-1 beta gene (2q13). Genes Brain Behav 2008; 7(7):796–801.
  6. Drexhage R., Knijff E, Padmos R, Heul-Nieuwenhuijzen L, Beumer W, Versnel M, et al. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother 2010; 10(1):59–76.
  7. Hope S, Ueland T, Steen NE, Dieset I, Lorentzen S, Berg AO, et al. Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder. Schizophr Res 2013; 145(1-3):36–42.
  8. Clerici M, Arosio B, Mundo E, Cattaneo E, Pozzoli S, Dell’Osso B, et al. Cytokine Polymorphisms in the Pathophysiology of Mood Disorders. CNS Spectr 2009; 14(8):419-25.
  9. Katila H, Appelberg B, Hurme M, Rimon R. Plasma levels of interleukin-1 beta and interleukin-6 in schizophrenia, other psychosis and affective disorder. Schizophr Res 1994; 12(1):29-34.
  10. Maes M, Bosmans E, Calabrese J, Smith R. Mettzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiat Res 1995; 29(2):141-52.
  11. Theodoropoulou ST, Sponakos G, Baxevanis CN, Economou M, Gritzapis AD, Papamichail MP, et al. Cytokines serum levels, outologous mixed lymphocyte reaction and chronically mediated schizophrenia patients. Schizophr Res 2001; 47(1):13-25. PMID:11163541
  12. Liu HC, Yong YY, Chou YM. Chen KP, Shen WW, Leo SJ. Immunologic variable in acute mania of bipolar disorder. J Neuroimmunol 2004; 150(1-2):116-22.
  13. Hope S, Dieset I, Agartz I, Steen NE, Ueland T, Melle I, et al. Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res 2011; 45(12):1608–16
  14. Rafiq S, Stevens K, Hurst AJ, Murray A, Henley W, Weedon MN, et al. Common genetic variation in the gene encoding interleukin-1-receptor antagonist (IL-1RA) is associated with altered circulating IL-1RA levels. Genes Immun 2007; 8(4):344–51.
  15. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009; 27:519-50.
  16. Papiol S, Rosa A, Gutie´rrez B, Martı´n B, Salgado P, Catala´n R, et al. Interleukin-1 cluster is associated with genetic risk for schizophrenia and bipolar disorder. J Med Genet 2004; 41(3):219-23.
  17. Smith AJ, Humphries SE. Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev 2009; 20(1):43-59.
  18. Munkholm K, Vinberg M, Kessing LV. Cytokines in bipolar disorder: A systematic review and meta-analysis. J Affect Disord 2013; 144(1-2):16–27.
  19. Kim SJ, Lee HJ, Koo HG, Kim JW, Song JY, Kim MK, et al. Impact of IL-1 receptor antogonist gene polymorphism on sohizophrenia and biopolar disorder. Psyohiatr Genet 2004; 14(3):165-7.
  20. Sharifi V, Assadi SM, Mohammadi MR, Amini H, Kaviani H, Semnani Y, et al. Structured Clinical Interview for DSM-IV (SCID): Persian translation and cultural adaptation. Iran J Psychiatry 2007; 1:46-8.
  21. Ghoreishizadeh MA, Amiri S, Pezeshki MZ, Bakhtshadi F, Ranjbar F. Validity of Persian Version of Mood Disorder Questionnaire in Diagnosis of Bipolar Mood Disorder in Depressive Phase. Iranian Journal of Psychiatry and Behavioral Sciences. 2011; 5(1): 50-55.
  22. Katila H, Hänninen K, Hurme M. Polymorphisms of the interleukin-1 gene complex in schizophrenia. Mol Psychiatry 1999; 4(2):179-81.
  23. Söderlund J, Olsson SK, Samuelsson M, Walther-Jallow L, Johansson C, Erhardt S, et al. Elevation of cerebrospinal fluid interleukin-1α in bipolar disorder. J Psychiatry Neurosci 2011; 36(2):114-8.
  24. Rady A, Elsheshai A, Abdallah I, Elkholy O, Abou el Wafa H. Interleukin 1 Beta Gene Polymorphism in Schizophrenia and Psychotic Depression. Gene Express Genet Genomics. 2010; 3: 7–12.
  25. Yu YW, Chen TJ, Hong CJ, Chen HM, Tsai SJ. Association study of the interleukin-1β(C-511T) genetic polymorphisms with major depressive disorder, associated symtomatology, and antidepressant response. Neuropsychopharmacology. 2003; 28: 1182–1185.
  26. Borkowska P, Kucia K, Rzezniczek S, Paul-Samojedny M, Kowalczyk M, Owczarek A, et al. Interleukin-1beta Promoter (−31T/C and −511C/T) Polymorphisms in Major Recurrent Depression. J Mol Neurosci 2011; 44(1):12–6.
  27. Williams HJ, Craddock N, Russo G, Hamshere ML, Moskvina V, Dwyer S, et al. Most genome wide significant susceptibility loci for schizophrenia and bipolar disorder reported to date cross-traditional diagnostic boundaries. Hum Mol Genet 2011; 20(2):387–91.
  28. -1 gene complex locus with susceptibility to schizophrenia in the Caucasian population. Schizophr Res 2010; 120(1-3):131-42.
  29. Saviouk V, Chow EW, Bassett AS, Brzustowicz LM. Tumor necrosis factor promoter haplotype associated with schizophrenia reveals a linked locus on 1q44. Mol Psychiatry 2005; 10(4):375-83.
  30. Hänninen K, Katila H, Saarela M, Rontu R, Mattila KM, Fan M, et al. Interleukin-1 beta gene polymorphism and its interactions with neuregulin-1 gene polymorphism are associated with schizophrenia. Eur Arch Psychiatry Clin Neurosci 2008; 258(1):10-5.
  31. Rosa A, Peralta V, Papiol S, Cuesta MJ, Serrano F, Martínez-Larrea A, et al. Interleukin-1beta (IL-1beta) gene and increased risk for the depressive symptom-dimension in schizophrenia spectrum disorders. Am J Med Genet B Neuropsychiatr Genet 2004; 124B(1): 10-4.]
  32. Meisenzahl EM, Rujescu D, Kirner A, Giegling I, Kathmann N, Leinsinger G, et al. Association of an interleukin-1beta genetic polymorphism with altered brain structure in patients with schizophrenia. Am J Psychiatry 2001; 158(8):1316-9.
  33. Sandoval H, Soares JC, Mwangi B, Asonye S, Alvarado LA, Zavala J, et al. Confirmation of MRI anatomical measurements as endophenotypic markers for bipolar disorder in a new sample from the NIMH Genetics of Bipolar Disorder in Latino Populations study. Psychiatry Res 2016; 247:34-41.
  34. Pomarol-Clotet E, Alonso-Lana S, Moro N, Sarró S, Bonnin MC, Goikolea JM, et al. Brain functional changes across the different phases of bipolar disorder. Br J Psychiatry 2015; 206(2):136-44.
  35. Potter ED, Ling ZD, Carvey PM. Cytokine-induced conversion of mesencephalic-derived progenitor cells into dopamine neurons. Cell Tissue Res 1999; 296(2):235–46.

IssueVol 15, No 6 (2016) QRcode
SectionOriginal Article(s)
Bipolar disorder Interleukin 1 gene cluster Iran Polymorphism

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Talaei A, Tavakkol Afshari J, Fayyazi Bordbar MR, Pouryousof H, Faridhosseini F, Saghebi A, Rezaei Ardani A, Talaei A, Tehrani M. A Study on the Association of Interleukin-1 Cluster with Genetic Risk in Bipolar I Disorder in Iranian Patients: A Case-control Study. Iran J Allergy Asthma Immunol. 2017;15(6):466-475.